'김갑성' 기자의 전체기사
-
Bestqool Honors Workers With Light-Based Recovery Solution…
From Aug 27 through Sep 4, all Bestqool Products will be available at unbeatable prices. NEW YORK, Aug. 27, 2025 -- After long hours of daily work, the body needs more than rest — it requires a sustainable, gentle, and easy-to-maintain recovery method. Bestqool, a health and wellness technology brand for light-based recovery, is celebrating this year's Labor Day with an important message: Honor your labor by protecting the body that does the work. For a limited time, Bestqool is offering 12% off all products from August 27th to September 4th, giving workers the opportun
- 김갑성 기자
- 2025-08-27 23:31
-
Fangzhou Posts Strong 1H Revenue and Profit as Physician…
HONG KONG, Aug. 27, 2025 -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across its healthcare services and internal operations. Net Profit Swings to Positive as Targeted User Base Unlocks Growth Fangzhou posted revenue of RMB 1.494 billion for the six months ended June 30, up 12.9% from a year earlier. Net profit reached RMB 12.5 mill
- 김갑성 기자
- 2025-08-27 23:09
-
Harbour BioMed Reports 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "In the first half of 2025, Harbour BioMed achieved several significant milestones. During the reporting period, the company's pro
- 김갑성 기자
- 2025-08-27 22:40
-
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 -- Key Highlights from the Financial Report: Revenue surged 404% year over year to RMB 517 million in the first half of 2025. Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. XtalPi was added to the MSCI China Small Cap Index, underscoring strong recognition of its investment value by the international capital markets. Significant breakthroughs and milestones were achieved across multiple business lines. Drug Discovery Solutions: The Deep Integration of Ad
- 김갑성 기자
- 2025-08-27 22:26
-
Advancing DEL Technology for the Research Lab: HitGen In…
Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug discovery. HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 – featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.0 comes in a convenient kit format that is accessible to scientists in industry and
- 김갑성 기자
- 2025-08-27 21:30
-
Neusoft Medical Systems Launches China's First Photon-Co…
SHENYANG, China, Aug. 27, 2025 -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector. Photon-counting CT (PCCT) is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector t
- 김갑성 기자
- 2025-08-27 21:03
-
NUHS SPEARHEADS AI-POWERED BRAIN CARE PROGRAMME TO TACKLE UNDE…
Novel initiative in Asia integrates predictive AI with personalised health coaching to empower early action and prevention SINGAPORE, Aug. 27, 2025 -- Dementia remains a hidden epidemic in Singapore, with slightly more than half of all cases going undiagnosed. According to the Well-being of the Singapore Elderly (WiSE) 2023[1] study, 51.5 per cent of dementia cases remain undetected. This is a troubling figure given that an estimated 45 per cent of dementia cases are preventable through early lifestyle interventions[2]. In an effort to close this gap, a multidisc
- 김갑성 기자
- 2025-08-27 21:00
-
Actinogen trial using intended commercial Xanamem tablet…
Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.
- 김갑성 기자
- 2025-08-27 20:00
-
Innovent Announces 2025 Interim Results and Business Upd…
[ 메디채널 김갑성 기자 ] Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces its 2025 interim results and major business updates. Dr. Michael Yu, Found
- 김갑성 기자
- 2025-08-27 18:08
-
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Re…
CHENGDU, China, Aug. 27, 2025 -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core product, Stapokibart, an IL-4Rα antibody marketed as Kang Yue Da®. The drug generated net sales of approximately RMB 170 million. Keymed strengthened its balance sheet with a successful placement raising ~HK$864 million, providing ample funds for pipeline development and commercialization.
- 김갑성 기자
- 2025-08-27 14:02
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-19_SUN
- Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 23:42
- HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet 23:37
- United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits 22:00
- Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting 15:00
- Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 14:00
- From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use 13:00
- 내면의 조화를 발견하세요: '원더풀 인도네시아 웰니스 페스티벌 2025' 개최 01:50
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 20일 01시 20분